Additionally, lipid nanoparticles (LNPs) can deliver SOX9 siRNA to silence the SOX9 gene in cancer cells, thereby suppressing the anti-tumor immune response—particularly by impairing CD8+ T cell function—and ultimately inhibiting tumor growth (Zhang et al., 2025). The gene discussed is CD8A; the disease is neoplasm.